February 23, 2018 / 7:13 AM / 3 months ago

BRIEF-FDA Accepts Shire's Biologics License Application

Feb 23 (Reuters) - Shire Plc:

* FDA ACCEPTS SHIRE’S BIOLOGICS LICENSE APPLICATION AND GRANTS PRIORITY REVIEW FOR LANADELUMAB FOR PREVENTION OF ATTACKS IN HEREDITARY ANGIOEDEMA PATIENTS​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below